- IN₹36.17bn
- IN₹41.70bn
- IN₹25.65bn
Brief: Aarti Drugs Says Approved Buyback Of Shares Worth Upto 598.5 Million Rupees
India's Aarti Drugs jumps on share buyback
India's Aarti Drugs jumps on share buyback proposal
Brief: Aarti Drugs US FDA Conducted Inspection At Unit's Manufacturing Facility At Baddi
India's Aarti Drugs gains after getting US FDA inspection report
Brief: Aarti Drugs Gets EIR From US FDA Concluding Inspection As Closed
Brief: Aarti Drugs Says In FY25, Anticipate Improvement In Margins Driven By Growth In Export Sales
Brief: Aarti Drugs June-Quarter Consol Net Profit 332.4 Mln Rupees
Brief: Aarti Drugs Says Co Directed To Voluntarily Stop Manufacturing Particular Product At Maharashtra Plant
Brief: Aarti Drugs Says Fire Occurred At N-198 Unit Located At Tarapur, Maharashtra
Brief: Aarti Drugs March-Qtr Consol Net Profit Falls
Brief: Aarti Drugs Says USFDA Inspected Unit's Formulations Manufacturing Facility In Himachal Pradesh
India's Aarti Drugs rises after Gujarat authority revokes closure of plant
Brief: Aarti Drugs Says Initiating Commercial Production Of Dermatology Product At Facility In Tarapur, Maharashtra
India's Aarti Drugs down after Q3 profit, rev fall
Brief: India's Aarti Drugs Sept-Quarter Consol Net Profit Rises Marginally
India's Aarti Drugs surges on Q1 profit rise and share buyback
Brief: India's Aarti Drugs June-Qtr Consol Net Profit Rises
India's Aarti Drugs climbs on Q4 profit growth